A patient uses their inhaler as prescribed, follows every instruction from their primary care provider, and still ends up back in the emergency room three months later. This scenario is common, and it usually isn’t a failure of the patient or the medication. More often, it’s a sign that an underlying driver of the disease was never identified in the first place.
The Allergy Connection Most Patients Never Hear About
Asthma is frequently treated as a single, uniform disease, but for most patients it isn’t. Somewhere between 60% and 90% of children with allergic asthma have
their attacks triggered by inhaled allergens, and the figure sits closer to 50% among adults. [1] CDC survey data tells a similar story: roughly two-thirds of children
aged 17 and under with current asthma also carry a diagnosed allergy.
Despite this, allergy testing is often skipped in routine asthma management, leaving the triggers unaddressed while the medication dose keeps climbing.
Allergic rhinitis is one of the strongest predictors of whether a child’s asthma will persist rather than resolve. In one pediatric cohort, children with
allergic rhinitis were nearly four times more likely to have persistent asthma symptoms a year later than children without nasal allergies. The upper and lower airways don’t
behave as separate systems—ongoing allergic inflammation in the nose is a strong signal that the lungs are dealing with the same problem.
WHAT THE DATA SHOWS:
- 60–90% of children with persistent asthma have allergen-triggered
attacks
- 50% of adults with persistent asthma share the same allergic
pattern
- 66% of U.S. children with current asthma have a diagnosed allergy
Why “Mostly Controlled” Isn’t Good Enough
When the underlying cause goes unaddressed, patients don’t just experience more symptoms—they suffer worse outcomes and incur higher costs. In the UK,
analysis of adults on combination inhaler therapy, and patients whose asthma was not well controlled were roughly 50% more likely to visit the emergency
department and 63% more likely to be hospitalized than patients with well-controlled disease. Moreover, their total direct and indirect costs were roughly double.
U.S. claims data shows a comparable pattern: patients with uncontrolled asthma spent nearly $3,900 more per year on asthma-related care than patients whose
disease was controlled. [5]
Much of that added burden traces back to oral corticosteroid bursts—commonly prescribed as a Medrol dose pack or a short course of prednisone—used to control flare-ups. Patients on these oral corticosteroids (OCS, for short) have a roughly 26% higher relative risk of an emergency department visit and a 14% higher risk of hospitalization than patients who avoid them. Repeated courses come with their own long-term risks, including osteoporosis and diabetes. [6] Beyond the clinical and financial toll, poorly controlled asthma disrupts daily life. Sleep, school attendance, and work productivity all decline meaningfully as control worsens. [4]
How an Allergy & Immunology Specialist Changes the Trajectory
This isn’t a reason to be discouraged. It’s a mandate to identify the root cause of the disease severity and is precisely the diagnostic gap an allergist/immunologist is trained to bridge.
Identifying and Addressing the Real Trigger
Skin and specific IgE testing replace guesswork with precise answers—identifying exact triggers like dust mites, pollen, mold, or pet dander. This allows treatment to be tailored to the patient’s unique needs rather than a generic asthma protocol.
Looking Beyond the Lungs
Asthma rarely exists in a vacuum. Chronic rhinosinusitis coexists in 50% to 70% of asthma cases, and nearly 1 in 6 patients has taken oral steroids for a sinus issue rather than a lung issue. [7, 8] This strongly suggests that upper airway inflammation drives lower airway instability. Furthermore, other diagnoses like gastroesophageal reflux compounds the problem through direct irritation and bronchospasm.⁹ Ultimately, treating these coexisting conditions often improves asthma control far more effectively than just increasing asthma medications.
Environmental Control That’s Actually Targeted
Blanket recommendations to “reduce allergen exposure” are vastly inferior to individualized environmental control plans. For instance, the interventions for dust mite sensitivity—such as allergen-impermeable encasements and humidity regulation—differ fundamentally from the guidance required for pollen-driven asthma.
Personalized Therapy, Including Allergen Immunotherapy
For patients with confirmed dust mite allergy, allergic rhinitis, and asthma that remains poorly controlled despite inhaled corticosteroids, GINA guidelines support adding house dust mite sublingual immunotherapy for adults—provided lung function is above 70% of predicted. [¹⁰] The clinical benefits are significant: in randomized trials, the highest-dose regimen allowed a 42% reduction in required inhaled steroids, compared to just 15% for placebo. [¹¹] Furthermore, real-world data tracking over 46,000 patients for a decade confirms that long-term use reduces exacerbations. [¹¹] Unlike daily medications that only suppress symptoms, immunotherapy is the original treatment capable of fundamentally modifying the disease course.
Biologics for Difficult-to-Control Disease
When optimized inhalers and comorbidity management aren’t enough, biologic therapies offer a powerful, targeted solution. These drugs block the exact pathways driving the inflammation: omalizumab targets IgE, mepolizumab and benralizumab address eosinophils, dupilumab blocks IL-4/IL-13, and tezepelumab works on alarmins benefiting patients regardless of biomarker levels. [12, 13] The clinical impact is dramatic. Across the entire drug class, biologics consistently prevent the severe exacerbations that drive ER visits and hospitalizations. [13] The key to this success is matching the biologic to the patient’s specific inflammatory phenotype—which is precisely the expertise of an allergist/immunologist.
The Takeaway
For many patients labeled with “difficult” or “treatment-resistant” asthma, the missing piece isn’t more steroid or a stronger inhaler—it’s an accurate understanding of what’s actually driving their disease. Allergists and immunologists provide solutions that go far beyond standard asthma management by utilizing allergy testing, evaluating comorbidities like rhinosinusitis and reflux, and offering targeted treatment plans including environmental guidance, immunotherapy, and biologics. .
If you or your child are managing asthma symptoms that don’t feel fully under control, a specialist evaluation can identify what’s been missed and build a plan
around it. Our team at Agape Allergy & Immunology Associates is here to help.
— Dr. Jackie Garrett, Agape Allergy & Immunology
References
- Al-Shwaiki H, et al. Sensitization to inhaled allergens in asthmatic children in southern Jordan. ncbi.nlm.nih.gov/pmc/articles/PMC6839227
- CDC. AsthmaStats: Allergy Prevalence Among U.S. Children by Current Asthma Status, 2022. cdc.gov/asthma/asthmastats
- Persistent Asthma at School Age: Associated Factors in Preschool Children with Asthma. ncbi.nlm.nih.gov/pmc/articles/PMC9856300
- The impact of poor asthma control among asthma patients treated with ICS+LABA in the United Kingdom. ncbi.nlm.nih.gov/pmc/articles/PMC5434793
- Clinical and Economic Burden of Uncontrolled Severe Noneosinophilic Asthma. AJMC. ajmc.com
- Canonica GW, et al. Burden of oral corticosteroid use in severe asthma. Allergy, 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12368757
- STAT6 Blockade Abrogates Aspergillus-Induced Eosinophilic Chronic Rhinosinusitis and Asthma. ncbi.nlm.nih.gov/pmc/articles/PMC8904741
- Comorbid Chronic Rhinosinusitis and Asthma: An EAACI Task Force Report. pmc.ncbi.nlm.nih.gov/articles/PMC13040647
- Chronic rhinosinusitis, asthma, and gastroesophageal reflux: Epidemiology, pathophysiology, and comorbidity.
sciencedirect.com/science/article/pii/S2949913525000084
- Global Initiative for Asthma (GINA). Summary Guide for Asthma Management and Prevention, 2024. ginasthma.org
- Allergen-specific immunotherapy for allergic asthma: What’s new? explorationpub.com/Journals/eaa/Article/100930
- Biologic Therapies in Severe Asthma: Current Landscape, Clinical Evidence, and Future Directions. link.springer.com/article/10.1007/s40124-025-00373-7
- Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an ED Visit in Patients with Uncontrolled Asthma. Advances in Therapy.
link.springer.com/article/10.1007/s12325-025-03184-w
- Current and Emerging Biologic Therapies for Severe Asthma. pmc.ncbi.nlm.nih.gov/articles/PMC13179240